Overview
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indication
Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.
Associated Conditions
- Clotting
- Deep Vein Thrombosis
- Pulmonary embolism, Deep vein thrombosis
- Venous Thromboembolism
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/04/17 | Phase 3 | Recruiting | |||
2023/08/31 | Phase 4 | Recruiting | |||
2023/02/21 | Phase 4 | Recruiting | |||
2022/11/23 | Phase 3 | Completed | Galician Research Group on Digestive Tumors | ||
2022/03/17 | Phase 2 | Recruiting | University Hospital, Linkoeping | ||
2022/01/05 | Phase 3 | Recruiting | Michalis Karamouzis | ||
2021/09/08 | N/A | UNKNOWN | University Hospital of Patras | ||
2021/03/12 | Phase 4 | Terminated | |||
2021/02/05 | Not Applicable | Active, not recruiting | |||
2021/01/29 | Not Applicable | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| INNOHEP | 02358182 | Solution - Subcutaneous | 20000 UNIT / ML | 9/13/2011 | |
| INNOHEP | 02358166 | Solution - Subcutaneous | 10000 UNIT / ML | 12/10/2011 | |
| INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML | 02167859 | Liquid - Subcutaneous | 11700 UNIT / ML | 12/31/1995 | |
| INNOHEP | 02167840 | Solution - Subcutaneous | 10000 UNIT / ML | 12/31/1995 | |
| INNOHEP | 02231478 | Solution - Subcutaneous | 20000 UNIT / ML | 9/23/1997 | |
| INNOHEP | 02358158 | Solution - Subcutaneous | 10000 UNIT / ML | 9/9/2011 | |
| INNOHEP | 02429462 | Solution - Subcutaneous | 8000 UNIT / 0.4 ML | 9/30/2014 | |
| LOGIPARIN LIQ SC 10000 FXAIU/ML | Novo Nordisk Canada Inc | 02056682 | Liquid - Subcutaneous | 10000 UNIT / ML | 12/31/1994 |
| INNOHEP | 02229755 | Solution - Subcutaneous | 10000 UNIT / ML | 7/31/1997 | |
| INNOHEP | 02229515 | Solution - Subcutaneous | 20000 UNIT / ML | 2/28/1997 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.